Exploring links between 2-oxoglutarate-dependent oxygenases and Alzheimer's disease.
Haotian LiuYong XieXia WangMartine I AbboudChao MaWei GeChristopher J SchofieldPublished in: Alzheimer's & dementia : the journal of the Alzheimer's Association (2022)
Hypoxia, that is, an inadequate oxygen supply, is linked to neurodegeneration and patients with cardiovascular disease are prone to Alzheimer's disease (AD). 2-Oxoglutarate and ferrous iron-dependent oxygenases (2OGDD) play a key role in the regulation of oxygen homeostasis by acting as hypoxia sensors. 2OGDD also have roles in collagen biosynthesis, lipid metabolism, nucleic acid repair, and the regulation of transcription and translation. Many biological processes in which the >60 human 2OGDD are involved are altered in AD patient brains, raising the question as to whether 2OGDD are involved in the transition from normal aging to AD. Here we give an overview of human 2OGDD and critically discuss their potential roles in AD, highlighting possible relationships with synapse dysfunction/loss. 2OGDD may regulate neuronal/glial differentiation through enzyme activity-dependent mechanisms and modulation of their activity has potential to protect against synapse loss. Work linking 2OGDD and AD is at an early stage, especially from a therapeutic perspective; we suggest integrated pathology and in vitro discovery research to explore their roles in AD is merited. We hope to help enable long-term research on the roles of 2OGDD and, more generally, oxygen/hypoxia in AD. We also suggest shorter term empirically guided clinical studies concerning the exploration of 2OGDD/oxygen modulators to help maintain synaptic viability are of interest for AD treatment.
Keyphrases
- endothelial cells
- cardiovascular disease
- early stage
- nucleic acid
- small molecule
- cognitive decline
- oxidative stress
- squamous cell carcinoma
- type diabetes
- spinal cord
- case report
- coronary artery disease
- preterm infants
- high throughput
- lymph node
- spinal cord injury
- blood brain barrier
- combination therapy
- replacement therapy
- low cost
- iron deficiency